CD22 Positive

• CD22 is a B-cell specific transmembrane glycoprotein that acts as an inhibitory co-receptor.
• The term CD22 Positive meaning refers to the expression of the CD22 protein on the surface of cells.
• CD22 positive cells function primarily in regulating B-cell activation and signaling, influencing immune responses.
• CD22 expression is a crucial diagnostic marker and therapeutic target in various CD22 positive diseases, especially B-cell malignancies.

What is CD22 Positive?

CD22 Positive refers to the presence of the CD22 protein on the surface of a cell. CD22, also known as Siglec-2, is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and the sialic acid-binding immunoglobulin-type lectin (Siglec) family. It is expressed exclusively on B lymphocytes, appearing during the late pro-B cell stage and persisting through mature B-cell development, but typically absent on plasma cells.

The CD22 positive meaning in a clinical context signifies that cells, often B lymphocytes, express this specific marker. This expression is detected using techniques such as flow cytometry or immunohistochemistry, which are vital for identifying and characterizing different cell populations. The uniform presence of CD22 on most B-cell lymphomas and leukemias makes it an invaluable diagnostic tool and a promising target for therapeutic interventions.

CD22 Positive Cells: Function and Role

The CD22 positive cells function primarily as a negative regulator of B-cell receptor (BCR) signaling. Upon binding to sialic acid-containing ligands on other cells or soluble molecules, CD22 recruits intracellular signaling molecules, notably the tyrosine phosphatase SHP-1, to its cytoplasmic tail. This recruitment leads to the dephosphorylation of key signaling proteins, thereby dampening the activation signals initiated by the BCR.

Beyond its inhibitory role, CD22 also influences B-cell adhesion, migration, and survival. Its ability to modulate B-cell activation is crucial for maintaining immune tolerance and preventing autoimmune responses. The multifaceted functions of CD22 include:

• Inhibiting B-cell receptor (BCR) signaling to prevent overactivation.
• Modulating B-cell proliferation and differentiation.
• Facilitating B-cell adhesion to other cells through its ligand-binding capabilities.
• Regulating B-cell survival pathways.

Understanding these functions is essential for comprehending the complex regulatory mechanisms governing B-cell biology and their implications in health and disease.

Diseases Associated with CD22 Positive Cells

The expression of CD22 on B cells makes it a critical marker in the diagnosis and treatment of various CD22 positive diseases, particularly B-cell malignancies. These include a range of lymphomas and leukemias where the cancerous cells retain CD22 expression.

Prominent examples of CD22 positive diseases include B-cell acute lymphoblastic leukemia (B-ALL) and many types of non-Hodgkin lymphoma (NHL), such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. For instance, B-ALL is the most common childhood cancer, and its B-cell subtype, which is typically CD22 positive, accounts for approximately 75-80% of all childhood leukemias, according to the American Cancer Society. The consistent expression of CD22 on these malignant cells makes it an excellent target for immunotherapy.

Therapeutic strategies leveraging CD22 include antibody-drug conjugates (ADCs) like inotuzumab ozogamicin, which delivers a potent cytotoxic agent directly to CD22-expressing cancer cells, minimizing systemic toxicity. Chimeric antigen receptor (CAR) T-cell therapies are also being explored and developed to target CD22, offering another promising avenue for patients with refractory or relapsed B-cell malignancies.